Neoleukin Therapeutics Cuts 70% of Workforce, CEO Jonathan Drachman to Step Down Amid Strategic Review
Neoleukin Therapeutics is cutting about 70% of its workforce and exploring strategic alternatives including sale or merger, with CEO Jonathan Drachman stepping down. The company’s stock rose by over 30% following the announcement.
No comments yet.